Black Rock Inc. Cullinan Oncology, Inc. Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
A detailed history of Black Rock Inc. transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 3,550,207 shares of CGEM stock, worth $29 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,550,207
Previous 2,428,993
46.16%
Holding current value
$29 Million
Previous $41.4 Million
49.59%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding CGEM
# of Institutions
155Shares Held
68.6MCall Options Held
15.6KPut Options Held
17.9K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$62.4 Million10.72% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$46.9 Million1.91% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.86MShares$31.5 Million0.74% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$27.9 Million15.23% of portfolio
-
Lynx1 Capital Management LP San Juan, PR3.22MShares$26.2 Million9.0% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $372M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...